Donna Culton, MD, University of North Carolina at Chapel Hill, outlines diagnosing autoimmune blistering diseases.

There are a few professions that particularly benefit from shoes or sneakers with really good traction — namely those who may be surrounded by spilled fluids or liquids, like restaurant workers or ...

If you’ve ever been told “you don’t fit the box” even though you can comfortably afford the payment, you’ve felt the limits of traditional mortgages. Non-QM loans exist for exactly that situation.

There’s been a significant shift in mortgage market composition, with non-conforming loans — including jumbo and non-QM products — climbing 4.39 percentage points year-over-year to reach 16.8% of ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on results from the pivotal ADEPT phase 2/3 ...

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that largely affects elderly patients, drugmakers Sanofi and Regeneron announced ...

More patients treated with dupilumab experienced sustained disease remission and itch reduction at week 36 compared with those who received placebo. The Food and Drug Administration (FDA) has approved ...

Dupilumab has been approved by the FDA for the treatment bullous pemphigoid in adults, the manufacturer Regeneron announced. In the study, 106 patients were randomized to 300 mg of subcutaneous ...

Dupilumab is now approved for bullous pemphigoid, showing efficacy in achieving sustained disease remission and reducing severity. The LIBERTY-BP ADEPT study demonstrated significant improvements in ...